AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.